Annexon (ANNX) to Release Quarterly Earnings on Monday

Key Points

• Annexon (NASDAQ:ANNX) is expected to report its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.36) per share for the quarter.
• The company's stock recently increased by 1.4%, reaching $2.49, and has a market cap of approximately $272.64 million.
• Several institutional investors have significantly increased their positions in Annexon, with AQR Capital Management boosting its stake by 122.6% in the first quarter.

Annexon (NASDAQ:ANNX - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Annexon to post earnings of ($0.36) per share for the quarter.

Annexon (NASDAQ:ANNX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.07). On average, analysts expect Annexon to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Annexon Price Performance

Shares of ANNX traded down $0.11 during mid-day trading on Wednesday, reaching $2.38. 130,623 shares of the company's stock traded hands, compared to its average volume of 1,567,669. The stock has a market cap of $260.56 million, a P/E ratio of -2.01 and a beta of 1.30. The stock's 50-day moving average is $2.48 and its two-hundred day moving average is $2.46. Annexon has a 12 month low of $1.28 and a 12 month high of $7.85.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Needham & Company LLC cut their target price on Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright dropped their price objective on Annexon from $20.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC boosted its position in Annexon by 31.1% during the 1st quarter. Acadian Asset Management LLC now owns 203,990 shares of the company's stock valued at $393,000 after acquiring an additional 48,345 shares in the last quarter. Jane Street Group LLC boosted its position in Annexon by 8.2% during the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company's stock valued at $193,000 after acquiring an additional 7,553 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in Annexon by 122.6% during the 1st quarter. AQR Capital Management LLC now owns 73,790 shares of the company's stock valued at $142,000 after acquiring an additional 40,637 shares in the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.